Cargando…

Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach

Acalabrutinib, a selective, covalent Bruton tyrosine kinase inhibitor, is a CYP3A substrate and weak CYP3A/CYP2C8 inhibitor. A physiologically‐based pharmacokinetic (PBPK) model was developed for acalabrutinib and its active metabolite ACP‐5862 to predict potential drug–drug interactions (DDIs). The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Diansong, Podoll, Terry, Xu, Yan, Moorthy, Ganesh, Vishwanathan, Karthick, Ware, Joseph, Slatter, J. Greg, Al‐Huniti, Nidal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656940/ https://www.ncbi.nlm.nih.gov/pubmed/31044521 http://dx.doi.org/10.1002/psp4.12408

Ejemplares similares

Exposure–response analysis of acalabrutinib and its active metabolite, ACP‐5862, in patients with B‐cell malignancies
por: Edlund, Helena, et al.
Publicado: (2021)

Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP‐5862, in patients with B‐cell malignancies and in healthy subjects using a population pharmacokinetic approach
por: Edlund, Helena, et al.
Publicado: (2021)

Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment
por: Xu, Yan, et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens
por: Cohen‐Rabbie, Sarit, et al.
Publicado: (2021)

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
por: Wu, Jingjing, et al.
Publicado: (2016)

Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors
por: Pilla Reddy , Venkatesh, et al.
Publicado: (2021)

Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamics
por: Mistry, Hitesh B., et al.
Publicado: (2019)

Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities
por: Al‐Huniti, Nidal, et al.
Publicado: (2020)

PB2205: A MECHANISTIC ABSORPTION AND PHARMACOKINETIC MODEL OF COVALENT BTK INHIBITOR TL-895: INFLUENCE OF FOOD AND ACID REDUCING AGENTS
por: Macwan, Joyce, et al.
Publicado: (2023)

PB2200: FOOD AND ACID REDUCING AGENT EFFECTS ON PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF THE COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) TL-895 IN HEALTHY SUBJECTS
por: Allard, Martine, et al.
Publicado: (2023)

Simulation and Prediction of the Drug‐Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling
por: Zhou, D, et al.
Publicado: (2016)

A novel LC-MS/MS method for simultaneous estimation of acalabrutinib and its active metabolite acalabrutinib M(27) in human plasma and application to a human pharmacokinetic study
por: Valluri, Venkat Rao, et al.
Publicado: (2022)

Predictive Performance of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling of Renally Cleared Drugs in Children
por: Zhou, W, et al.
Publicado: (2016)

Population Exposure‐Response Modeling Supported Selection of Naloxegol Doses in Phase III Studies in Patients With Opioid‐Induced Constipation
por: Al‐Huniti, Nidal, et al.
Publicado: (2017)

Pharmacokinetics and Macrophage Inhibitory Cytokine‐1 Pharmacodynamics of the Murine Double Minute 2 Inhibitor, Navtemadlin (KRT‐232) in Fed and Fasted Healthy Subjects
por: Wong, Shekman, et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations
por: Pilla Reddy, Venkatesh, et al.
Publicado: (2018)

Development, Verification, and Prediction of Osimertinib Drug–Drug Interactions Using PBPK Modeling Approach to Inform Drug Label
por: Pilla Reddy, Venkatesh, et al.
Publicado: (2018)

Use of modeling and simulation to predict the influence of triazole antifungal agents on the pharmacokinetics of zanubrutinib and acalabrutinib
por: Chen, Lu, et al.
Publicado: (2022)

A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug–Drug Interaction Perpetrators
por: Marok, Fatima Zahra, et al.
Publicado: (2023)

Acalabrutinib: Disseminated aspergillosis: case report
Publicado: (2022)

Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia
por: Pu, Xia, et al.
Publicado: (2021)

Quantitative Prediction of Drug–Drug Interactions Involving Inhibitory Metabolites by Physiologically Based Pharmacokinetic Models: Is it Worth It?
por: Tod, M, et al.
Publicado: (2017)

Impact of Disease and Treatment Response in Drug–Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non‐Small Cell Lung Cancer
por: Vishwanathan, Karthick, et al.
Publicado: (2019)

Reporting guidelines for population pharmacokinetic analyses
por: Dykstra, Kevin, et al.
Publicado: (2015)

The role of acalabrutinib in adults with chronic lymphocytic leukemia
por: Fakhri, Bita, et al.
Publicado: (2021)

NICE recommends acalabrutinib for chronic lymphocytic leukaemia
Publicado: (2021)

PB1861: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, T., et al.
Publicado: (2022)

PB1948: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, Tatyana, et al.
Publicado: (2023)

Response to “Quantitative Prediction of Drug‐Drug Interactions Involving Inhibitory Metabolites by Physiologically Based Pharmacokinetic Models: Is It Worth?”
por: Templeton, IE, et al.
Publicado: (2017)

ACP basic statistics = ACP, statistiques de base.
Publicado: (1985)

Quantitative Prediction of Drug–Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?
por: Templeton, IE, et al.
Publicado: (2016)

Prediction of Drug–Drug–Gene Interaction Scenarios of (E)-Clomiphene and Its Metabolites Using Physiologically Based Pharmacokinetic Modeling
por: Kovar, Christina, et al.
Publicado: (2022)

Population pharmacokinetics modeling and exposure‐response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer
por: Nguyen, Jenny‐Hoa, et al.
Publicado: (2022)

Acalabrutinib for mantle cell lymphoma, chronic lymphocytic leukaemia
Publicado: (2020)

Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions
por: Series, Jennifer, et al.
Publicado: (2019)

Acalabrutinib in management of chronic lymphocytic leukemia: An Indian perspective
por: Sood, Nitin, et al.
Publicado: (2021)

Acalabrutinib in Membranous Nephropathy Associated With Chronic Lymphocytic Leukemia
por: Izzedine, Hassan, et al.
Publicado: (2022)

Editorial: Pharmacokinetic Evaluation and Modeling of Clinically Significant Drug Metabolites
por: Mircioiu, Constantin, et al.
Publicado: (2021)

Clinical evaluation of the potential drug–drug interactions of savolitinib: Interaction with rifampicin, itraconazole, famotidine or midazolam
por: Ren, Song, et al.
Publicado: (2021)

GCNCPR-ACPs: a novel graph convolution network method for ACPs prediction
por: Wu, Xiujin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bcaoca2q9ups4clk956jgj1srb